Panasal

Panasal was a clinical-stage pharmaceutical company focused on the development of a proprietary liquid formulation of aspirin (acetylsalicylic acid). The company's lead product candidate, also named Panasal, was designed to provide a significantly faster onset of action compared to traditional solid aspirin tablets, which is a critical factor in the emergency treatment of acute myocardial infarction. By utilizing a liquid delivery system, the company aimed to achieve rapid platelet inhibition and improve the gastrointestinal safety profile of the drug. Although the company conducted Phase 2 clinical trials to demonstrate the pharmacokinetic benefits of its formulation, it is no longer active in the biotechnology sector.